Capital International Ltd. CA Has $15.75 Million Stock Position in Amgen Inc. $AMGN

Key Points

• Capital International Ltd. CA boosted its position in Amgen by 81.6% in Q3, acquiring an additional 25,071 shares to hold 55,813 shares valued at about $15.75 million.
• Amgen beat quarterly expectations with $5.29 EPS versus $4.76 estimates and $9.87 billion in revenue (up 8.6% YoY), and set FY2026 EPS guidance of 21.60–23.00.
• Institutional investors own about 76.5% of Amgen, with multiple large funds increasing stakes and analysts ranging from Sell to Buy but showing a consensus rating of "Hold."

Capital International Ltd. CA increased its position in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 81.6% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 55,813 shares of the medical research company's stock after acquiring an additional 25,071 shares during the quarter. Capital International Ltd. CA's holdings in Amgen were worth $15,750,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Capital International Inc. CA lifted its holdings in shares of Amgen by 22.8% in the third quarter. Capital International Inc. CA now owns 386,784 shares of the medical research company's stock valued at $109,150,000 after purchasing an additional 71,908 shares in the last quarter. Capital International Investors grew its holdings in shares of Amgen by 1.5% during the third quarter. Capital International Investors now owns 19,192,995 shares of the medical research company's stock valued at $5,414,296,000 after buying an additional 282,219 shares in the last quarter. Capital Group Investment Management PTE. LTD. raised its position in Amgen by 93.4% during the third quarter. Capital Group Investment Management PTE. LTD. now owns 11,732 shares of the medical research company's stock valued at $3,311,000 after buying an additional 5,666 shares during the period. Bank of Montreal Can lifted its stake in Amgen by 5.3% in the 3rd quarter. Bank of Montreal Can now owns 1,063,079 shares of the medical research company's stock worth $300,001,000 after acquiring an additional 53,566 shares in the last quarter. Finally, Legal & General Group Plc boosted its position in Amgen by 5.0% during the 3rd quarter. Legal & General Group Plc now owns 3,716,957 shares of the medical research company's stock worth $1,048,925,000 after acquiring an additional 177,325 shares during the period. Institutional investors and hedge funds own 76.50% of the company's stock.

Amgen Stock Performance

NASDAQ AMGN opened at $376.97 on Tuesday. The company's fifty day moving average is $354.21 and its two-hundred day moving average is $323.38. Amgen Inc. has a 52-week low of $261.43 and a 52-week high of $391.29. The company has a debt-to-equity ratio of 5.78, a current ratio of 1.14 and a quick ratio of 0.90. The firm has a market capitalization of $203.21 billion, a price-to-earnings ratio of 26.49, a P/E/G ratio of 3.67 and a beta of 0.45.

Amgen (NASDAQ:AMGN - Get Free Report) last released its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, beating the consensus estimate of $4.76 by $0.53. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The business had revenue of $9.87 billion during the quarter, compared to analysts' expectations of $9.46 billion. During the same quarter last year, the company earned $5.31 earnings per share. The firm's revenue was up 8.6% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Equities research analysts forecast that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be given a dividend of $2.52 per share. The ex-dividend date is Friday, May 15th. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.7%. Amgen's dividend payout ratio (DPR) is 70.84%.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on AMGN. TD Cowen reissued a "buy" rating on shares of Amgen in a research report on Wednesday, February 4th. Sanford C. Bernstein cut Amgen from an "outperform" rating to a "market perform" rating and set a $335.00 price target for the company. in a research note on Tuesday, January 20th. The Goldman Sachs Group lifted their target price on shares of Amgen from $403.00 to $415.00 and gave the company a "buy" rating in a research note on Wednesday, February 4th. Citigroup increased their price target on shares of Amgen from $315.00 to $345.00 and gave the stock a "neutral" rating in a research note on Wednesday, February 4th. Finally, Erste Group Bank upgraded Amgen from a "hold" rating to a "buy" rating in a report on Friday, December 5th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, twelve have given a Hold rating and two have issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus price target of $354.17.

About Amgen

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.